Mindray
Mindray Medical International Limited, commonly known as Mindray, is a leading global provider of medical devices and solutions, headquartered in Shenzhen, China (CN). Founded in 1991, the company has established a strong presence in key operational regions, including North America, Europe, and Asia, making significant strides in the healthcare industry. Specialising in innovative medical technologies, Mindray focuses on areas such as patient monitoring, in-vitro diagnostics, and ultrasound imaging. Its core products are distinguished by their advanced features and user-friendly designs, catering to the diverse needs of healthcare professionals. With a commitment to quality and innovation, Mindray has achieved notable milestones, including numerous industry awards and recognitions, solidifying its position as a trusted partner in healthcare worldwide.
DitchCarbon Score
How does Mindray's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mindray's score of 37 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mindray's reported carbon emissions
In 2024, Mindray reported total carbon emissions of approximately 53,279,800 kg CO2e for Scope 1, 68,619,750 kg CO2e for Scope 2, and 94,210,380 kg CO2e for Scope 3, resulting in a combined total of about 73,947,730 kg CO2e for Scope 1 and 2. This data reflects a comprehensive approach to emissions reporting, including all three scopes. For 2023, Mindray's emissions in the UK were significantly lower, with Scope 2 emissions at about 25,700 kg CO2e and Scope 3 emissions reaching approximately 2,769,470 kg CO2e. The breakdown of Scope 3 emissions included business travel (about 254,890 kg CO2e), employee commute (approximately 224,040 kg CO2e), and upstream transportation and distribution (around 2,185,770 kg CO2e). Mindray has set ambitious targets to reduce greenhouse gas (GHG) emissions intensity by 25% by 2030, using 2021 as the baseline year. This commitment applies to both Scope 1 and Scope 2 emissions, demonstrating a proactive stance towards climate action. The emissions data is cascaded from its parent company, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., ensuring consistency and accountability in reporting. Mindray's initiatives align with industry standards, reflecting a commitment to sustainability and responsible corporate practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mindray is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
